scholarly journals Deterioration in Sleep Quality Affects Cognitive Depression in Prostate Cancer Patients

2021 ◽  
Vol 15 (2) ◽  
pp. 155798832110012
Author(s):  
Christopher F. Sharpley ◽  
David R. H. Christie ◽  
Vicki Bitsika
Keyword(s):  
Prostate Cancer ◽  
Sleep Quality ◽  
Treatment Options ◽  
Depression Scale ◽  
Severity Index ◽  
Sleep Difficulty ◽  
Specific Symptom ◽  
Falling Asleep ◽  
Index Comparison ◽  
Sleep Difficulties

Men who suffer from prostate cancer (PCa) need to make important decisions regarding their treatment options. There is some evidence that these men may suffer from sleep difficulties due to their cancer or its diagnosis and treatment. Although sleep difficulties have been associated with cognitive depression in other samples of men, they have not been examined in PCa patients, despite the importance of decision-making for these men. This study was designed to investigate the association between sleep difficulties and cognitive depression in PCa patients. A sample of 96 PCa patients completed a background questionnaire, the Zung Self-Rating Depression Scale, and the Insomnia Severity Index. Comparison was made between sleep difficulty scores from before the patients received their diagnosis of PCa to the time of survey, allowing use of a “retrospective pretest” methodology. Just over 61% of the sample reported a deterioration in sleep quality, and this was significantly associated with cognitive depression ( r = .346, p = .007). At the specific symptom level, having a clear mind significantly contributed to the variance in difficulty falling asleep (R2 change = .140, F for change = 9.298, p = .003). Sleeping difficulties, particularly falling asleep, are common and associated with depression-related to ability to think clearly in PCa patients. This has potentially adverse effects upon the ability of men with PCa to understand their treatment options and make decisions about them.

scholarly journals 0482 A Preliminary Study on the Efficacy of Forehead-Cooling for Relieving Menopausal Sleep Difficulties and Hot Flashes

SLEEP ◽  
2020 ◽  
Vol 43 (Supplement_1) ◽  
pp. A185-A185
Author(s):  
F C Baker ◽  
M de Zambotti ◽  
L Chiappetta ◽  
E Nofzinger
Keyword(s):  
Sleep Quality ◽  
Hot Flashes ◽  
Severity Index ◽  
Cooling Device ◽  
Hot Flash ◽  
Subjective Sleep ◽  
Preliminary Study ◽  
Insomnia Symptoms ◽  
Sleep Difficulties ◽  
Insomnia Severity

Abstract Introduction Many women experience sleep difficulties in the approach to menopause and post-menopause, with about 25% experiencing severe symptoms that impact daytime functioning and quality of life. Hot flashes contribute to these sleep difficulties, being associated with nocturnal awakenings, poorer sleep quality, and chronic insomnia. New non-pharmacological sleep solutions have become available, including a forehead cooling device designed to target elevated brain metabolism in insomnia sufferers. Here, we explored whether this device was effective in improving subjective sleep and hot flashes in menopausal-age women with insomnia symptoms. Methods This study was an open-label, in-home investigation of the efficacy of nightly treatment with a forehead cooling device in 20 women (55.1 ± 4.2 years) with insomnia symptoms and daily hot flashes. Participants completed daily diaries assessing sleep quality and hot flashes across a baseline week (no treatment) followed by 4 weeks of treatment. They also completed questionnaires before and after treatment including the insomnia severity index and the hot flash related daily interference scale. Results Women reported better sleep quality with a shorter sleep onset latency and fewer awakenings (between 14-30% improvement) during the first week of device use, with further improvements over time, relative to baseline (p <0.001). Women also reported fewer nocturnal hot flashes that were less severe during treatment (p<0.001). They had lower insomnia severity scores post-treatment (9.3±5.8) compared to pre-treatment (20.0±5.7) (p<0.001), with 17 participants showing a reduction of 6 points or greater on the insomnia severity index. There was also a significant reduction in hot flash related daily interference post-treatment (p<0.001). Conclusion Use of a forehead cooling device during the night improved subjective sleep quality and reduced insomnia symptoms and hot flash frequency and severity in this preliminary study of menopausal-age women. Further large scale randomized controlled trials are required to determine efficacy. Support Ebb Therapeutics

scholarly journals COGNITIVE IMPAIRMENT AND SLEEP DIFFICULTIES OVER 10 YEARS IN A NATIONAL SAMPLE OF OLDER ADULTS

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S453-S453
Author(s):  
Rebecca Robbins ◽  
Amanda Sonnega ◽  
Robert W Turner II ◽  
Girardin Jean-Louis ◽  
Kenneth Langa
Keyword(s):  
Cognitive Impairment ◽  
Cognitive Function ◽  
Cognitive Functioning ◽  
Summary Score ◽  
Linear Regression Models ◽  
Sleep Difficulty ◽  
Falling Asleep ◽  
Nationally Representative ◽  
Sleep Difficulties ◽  
Over Time

Abstract Prior studies suggest that sleep difficulties (e.g., trouble falling asleep) may be associated with cognitive impairment. We used a large, nationally representative longitudinal survey of adults over the age of 50 in the US to examine the relationship between sleep difficulties and cognitive functioning. Generalized estimation equation (GEE) linear regression models were used to analyze data from the 2004-2014 waves of the Health and Retirement Study. We examined sleep difficulties and cognitive functioning within participants and across time (n=17,642). Sleep difficulty was measured as trouble falling asleep, nocturnal awakenings, and waking too early scored as 1= rarely/never, 2=sometimes, and 3=most of the time. A summary score indicated cognitive functioning (range 0-27). Models controlled for age, gender, race/ethnicity, marital status, education, chronic medical conditions, depressive symptoms, and body mass index (BMI). Compared to those with no sleep difficulties, those who reported difficulty falling asleep [“sometimes” OR=0.83,95%CI:0.71-0.96 and “most of the time” OR=0.79,95%CI: 0.64-0.98] and waking too early [“most of the time” OR=0.79,95%CI: 0.63-0.98] had worse cognitive functioning. Compared to those with no sleep difficulties, those who reported nocturnal awakenings [“most of the time” OR=1.29,95%CI:1.08-1.54] had higher cognitive functioning. Over time, lower cognitive function was more likely among those reporting difficulty falling asleep (OR=0.73,95%CI:0.54-0.97), nocturnal awakenings (OR=0.77,95%CI:0.61-0.97) and waking too early (OR=0.65,95%CI: 0.47-0.88). In this nationally representative, longitudinal sample of older US adults, we found that over time lower cognitive function was more likely among those who reported difficulty falling asleep, nocturnal awakenings, and waking too early.

scholarly journals Diagnostic tools for the root causes of desynchronosis in students who are professionally involved in sports

2019 ◽  
Keyword(s):  
Sleep Quality ◽  
Biological Clock ◽  
Severity Index ◽  
Living Conditions ◽  
Open Educational Resources ◽  
The Body ◽  
Diagnostic Tools ◽  
Sleep Cycle ◽  
Biological Clocks ◽  
Falling Asleep

The structure of the human biological rhythm is most sensitive to changes that occur when you alter usual living conditions. That is why the authors of the work devoted their attention to the study of its basic parameters such as the analysis of the daily regimen, taking into account the “wakefulness and rest” cycles, the sleep quality index, the severity of insomnia. These parameters directly affect the person’s efficiency and results of sports activities. The authors have developed a system for the electronic diagnosis of human biorhythms. You can get acquainted with it at the open educational resources of V.N.Karazin Kharkiv National University. In the work, for the first time, the basic cycles of “wakefulness and sleep”, “activity and rest” were evaluated as basic cycles of the day regimen of students professionally involved in sports using electronic diagnostics. Insomnia severity index was evaluated, which directly affects the psychosomatic state and can be a cause of violation of the dynamic stereotype of a person, deterioration of health. These factors contribute to the development of desynchronosis. The data obtained indicate that the surveyed group of individuals can quite easily adapt to work both in the morning and in the evening, but it is likely that these individuals have unnatural types of daily working capacity, which are manifestations of adaptation to new living conditions. Also, this group of people is characterized by medium and high levels of sleep quality and body recovery. It is easier for people of this group to fall asleep in non-standard conditions than to stay awake at unusual time. Modern youth, despite an active (sporty) lifestyle, has certain violations in the duration and nature of sleep. The data obtained indicate that reducing the duration of sleep by 1.3–1.5 hours directly affects the state of wakefulness and sleep during the day. Despite the fact that chronic sleep deprivation in this group of students professionally involved in sports has not been identified, some individual variations in the need for quality of sleep are revealed, after a long sleep, there is minimal improvement in daytime wakefulness, reduction of fatigue, improvement in the processes of memory, perception and concentration. All these indicators directly affect the sports result. Compensation of lack of nocturnal sleep is mainly possible only due to longer breaks for rest during the day. Thus, the need for sleep is determined on the one hand by the processes of relaxation and fatigue, which increase during wakefulness, and the circadian process – the cycle of “activity and rest”. The level of need for sleep increases during wakefulness and decreases during sleep, while the circadian rhythm is an independent component under the control of the internal biological clock. Thus, the need for sleep at any given moment is a summation of the processes of “activity and rest”, “wakefulness and sleep” and internal biological clocks, and disturbances in the interaction of these processes explain subjective experiences associated with disruption of the daily rhythm at abrupt changes in the daily pattern and changes of length of daylight. Therefore, when the time of falling asleep falls on the period of activity and the person cannot fall asleep, and feels constant drowsiness during the day due to the growing need for sleep, this is a violation of the “wakefulness and sleep” cycle associated with new living conditions and stress loads on the body.

scholarly journals Omega-3 in The Treatment of Mood and Sleep Disorders Induced by Hormone Therapy in Women with Breast Cancer: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial

2021 ◽  
Author(s):  
Behzad Nourosi ◽  
Erfan Naghsh ◽  
Sahar Esmaeil zadeh ◽  
Valiollah Mehrzad ◽  
Ali Darakhshandeh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Sleep Quality ◽  
Hormone Therapy ◽  
Mood Disorders ◽  
Intervention Group ◽  
Depression Scale ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Omega 3 ◽  
Falling Asleep

Abstract Purpose This study was performed to investigate the effect of omega-3 on the treatment of mood and sleep disorder induced by menopausal complications due to hormone therapy in patients with breast cancer. Methods A placebo, double-blind and controlled trial was designed in oncology-hematology outpatient’s clinic of Omid Hospital, Isfahan, Iran. First, sixty patients were screened by hospital anxiety and depression scale (HADS) for any baseline mood disorders and then divided into either intervention group who had received 2 grams’ omega-3 daily for 4 weeks or identical placebo. Then, the patients were considered to assess by center for epidemiological studies-depression scale (CES-D), profile of mood states (POMS), and Pittsburgh sleep quality index (PSQI) questionnaires at the baseline and after 4-week follow-up. Results Findings showed that the mean scores of CES-D (P = 0.002), POMS (P = 0.03), and PSQI (P = 0.04) were significantly lower in the intervention group than the control group. In the intervention group, mean scores of CES-D (P <0.001), POMS (P <0.001), and PSQI (P = 0.003) were significantly lower in post-intervention than pre-intervention. Mean changes in scores of CES-D (P = 0.01), POMS (P = 0.001), and PSQI (P = 0.02) were significantly higher in the intervention group than the control group. Conclusion Our findings revealed that omega-3 supplementation have the potential to reduce mood disorders as well as to improve sleep quality in terms of subjective sleep quality, delay in falling asleep, sleep delay, and sleep disturbance in patients with breast cancer.

Multimodal therapy for the treatment of fatigue in patients with prostate cancer receiving androgen deprivation therapy and radiation.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. TPS9650-TPS9650
Author(s):  
Sriram Yennurajalingam ◽  
Cindy Carmack ◽  
Karen Basen-Engquist ◽  
James M. Reuben ◽  
Eduardo Bruera
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Inflammatory Cytokines ◽  
Depressed Mood ◽  
Treatment Options ◽  
Depression Scale ◽  
Androgen Deprivation ◽  
Post Intervention ◽  
To Receive

TPS9650 Background: Cancer-related fatigue (CRF) is the most frequently reported symptom associated with cancer and its treatment. Unfortunately, there are limited treatment options to alleviate this distressing symptom. Preliminary data suggest that the combination of exercise, cognitive behavioral therapy (CBT), and methylphenidate (that is, multimodality therapy [MMT]) can play an important role in reducing CRF. The project’s objective is to explore the effects and safety of this MMT on CRF in prostate cancer patients scheduled to receive radiotherapy with androgen deprivation therapy. We hypothesizethat the MMT is capable of reducing CRF as measured by the FACIT-F subscale in prostate cancer patients scheduled to receive radiotherapy. Specific Aims:(1) Our primary aim is to obtain preliminary estimates of the effects of various treatments (exercise, CBT, and methylphenidate) and their combinations in reducing CRF in prostate cancer patients receiving radiotherapy, as measured by the change in patients’ FACIT-F subscale scores taken at baseline and on day 57 and the secondary objective is to determine the effects of the treatments and their combinations on anxiety and depressed mood (both measured by the Hospital Anxiety Depression Scale [HADS]); on physical activity and function (measured by an accelerometer and a handgrip dynamometer, respectively); on levels of inflammatory cytokines (IL-1β, IL-6, TNF-α, and IL-10) in serum and induced monocytes, before and after treatment Methods: For this study, we will use a randomized factorial design to assess 3 treatments (exercise, CBT, and methylphenidate) and their placebos in 8 replications. A total of 32 patients will receive each primary treatment and 32 will not. Patients will be studied for a 57-day period, during which they are scheduled undergo daily radiation treatments with androgen deprivation therapy. Fatigue, anxiety and depressed mood, and inflammatory cytokines will be determined at baseline and at 3 subsequent post-intervention assessments. After successful initiation so far 19/64 patients were enrolled. Accrual continues. Clinical trial information: NCT01410942.

scholarly journals The Development and Application of a Resilience-Promoting Program Using Changes in Sleep-Related Habits in Korean Adolescents

2021 ◽  
Vol 3 (3) ◽  
pp. 112-119
Author(s):  
Hyoseung Kang ◽  
So-Jin Lee ◽  
Bong-Jo Kim ◽  
Cheol-Soon Lee ◽  
Boseok Cha ◽  
...  
Keyword(s):  
Sleep Quality ◽  
Light Exposure ◽  
Sleep Onset ◽  
Depression Scale ◽  
Smart Phone ◽  
Severity Index ◽  
Short Version ◽  
Sleep Habits ◽  
Sleep Habit ◽  
Resilience Scale

Objective: Resilience-promoting program which covers strategies to improve sleep health through modulation of sleep-related habits has been lacking. The authors aimed to develop a resilience-promoting program that incorporates the encouragement of healthy sleep habits. Methods: Fifty-eight adolescents (27 female, 46.6%; aged 13.78±0.82 years) were recruited to test the effectiveness of the program. Dur- ing the first and final sessions, several self-reported questionnaires, including the Connor-Davidson Resilience Scale (CD-RISC), the Smart- phone Addiction Scale–short version (SAS-SV), Hospital Anxiety and Depression Scale (HADS), Composite Scale of Morningness (CSM), In- somnia Severity Index (ISI), and a sleep habit-related questionnaires were administered to the adolescents. After the first session, adolescents were provided with an Actiwatch and were asked to wear the watch to the last session date. Multiple linear regression analyses were used to identify predictors of resilience and sleep quality.Results: The participants’ resilience, morningness, sleep quality, wake after sleep onset (WASO), and wakening frequency during the night changed significantly. Resilience at the last session was related to sleep quality (β=-0.394, p=0.005) at the last session when controlling for age, sex, and morningness. Sleep quality at the last session was related to the mean sun- light exposure time (β=-0.363, p=0.037) at the last session when controlling for age, sex, and WASO during the third week.Conclusion: This study found that four weekly sessions of resilience-promoting program improved resilience, sleep quality including objective actigraphic measures, and morningness. Improved resilience was related to better sleep quality.

382 Measuring Daytime Sleepiness in Insomnia Disorder

SLEEP ◽  
2021 ◽  
Vol 44 (Supplement_2) ◽  
pp. A151-A152
Author(s):  
Rachel Manber ◽  
Norah Simpson ◽  
Jessica Dietch ◽  
Joshua Tutek ◽  
Isabelle Tully
Keyword(s):  
Daytime Sleepiness ◽  
Geriatric Depression Scale ◽  
Depression Scale ◽  
Severity Index ◽  
Stepped Care ◽  
Excessive Sleepiness ◽  
Insomnia Disorder ◽  
Obstructive Sleep ◽  
Falling Asleep ◽  
Clinical Measures

Abstract Introduction The EPWORTH Sleepiness Scale (ESS) is correlated with clinical parameters among patients with obstructive sleep apnea. However, its clinical relevance among patients with insomnia disorder is not clear. These patients often do not report daytime sleepiness nor have abnormal MSLT scores, but many do experience sleepiness in the evening. As a result, the ESS may not be the most appropriate measure for assessing daytime sleepiness among insomnia patients. This study aimed to evaluate clinical correlates of ESS among patients with insomnia. It also examined correlates of two items from the PROMIS item bank that specifically probe daytime sleepiness. Methods We used baseline data from 141 participants with insomnia disorder (mean age = 63.1y [SD 8.2]; 72% female) in the RESTING study (RCT of the Effectiveness of Stepped-Care Sleep Therapy In General Practice). Clinical measures: the Insomnia Severity Index (ISI), the Geriatric Depression Scale (GDS), and the Morningness Eveningness Questionnaire (MEQ). ESS&gt;10 defined excessive sleepiness. Two PROMIS items assessed frequency of being sleepy and of having trouble staying awake during the day, with ratings of ‘quite a bit’ and ‘very much’ classified as excessively sleepy. Results The ESS did not correlate with any of the clinical variables (ISI, GDS, MEQ). Correlations with these three variables with the PROMIS Sleepiness were .36, .22, and -.24 and with the PROMIS Excessive Sleepiness .28, .31, and -.17. Of the 38 participants with ESS&gt;10, 80% were not excessively sleepy per PROMIS. PROMIS Excessive Sleepiness classified only 9 participants as excessively sleepy, of which 7 (78%) were not classified by the ESS as excessively sleepy. Conclusion These results suggest that the ESS might not be a clinically relevant measure among people with insomnia disorder and that the PROMIS items may better capture sleepiness and excessive sleepiness during the daytime in this patient group. The divergence of the two measures might relate to whether instructions specify daytime as the period assessed, since people with insomnia may be more likely to experience evening, rather than daytime, sleepiness. It might also relate to differences in item wording (i.e., struggling to stay awake [PROMIS] versus likelihood of falling asleep [ESS]). Support (if any) 1R01AG057500

Effect of chronic kidney diseases-associated pruritus on patients’ sleep quality, well-being and its management

2020 ◽  
Vol 3 (1) ◽  
Author(s):  
Inayat Ur Rehman ◽  
Tahir Mehmood Khan
Keyword(s):  
Sleep Quality ◽  
Treatment Time ◽  
Kidney Diseases ◽  
Treatment Options ◽  
Well Being ◽  
Chronic Kidney Diseases ◽  
Comprehensive Management ◽  
Falling Asleep ◽  
Vital Effect

Chronic kidney diseases-associated pruritus (CKD-aP) affects the patients’ mental and physical health, potentially resulting in fatigue, depression, and directly affecting quality of sleep. Hemodialysis patients were reported to experiencing moderate to extreme CKD-aP, thus exhibited higher possibilities of remaining awake at night while sleeping in the day. Therefore, CKD-aP is attributed toward nocturnal awakenings and difficulty falling asleep. This condition (CKD-aP) significantly impacts the quality of life (QOL), triggering sleep disturbance, mood changes, and uncontrollable scratching. CKD-aP patients have a compromised QOL that is generally linked to limited personal freedom and control due to lengthy treatment time. Overall, the loss of freedom has wider implications, such as altering marital, family, and social relationships.Thus, this writing highlights the vital effect of chronic kidney diseases-associated pruritus on patients’ sleep quality, social and mental well-being and providing comprehensive management and treatment options to improve patients’ qualityof life.

Activation of the intrinsic-apoptotic pathway in LNCaP prostate cancer cells by genistein- topotecan combination treatments

2013 ◽  
Vol 3 (3) ◽  
pp. 66 ◽  
Author(s):  
Vanessa Hörmann ◽  
Sivanesan Dhandayuthapani ◽  
James Kumi-Diaka ◽  
Appu Rathinavelu
Keyword(s):  
Prostate Cancer ◽  
Cell Death ◽  
Cancer Cells ◽  
Apoptotic Cell ◽  
Treatment Options ◽  
Attractive Alternative ◽  
Intrinsic Apoptotic Pathway ◽  
Prostate Cancer Cells ◽  
Apoptotic Pathway ◽  
Combination Treatments

Background: Prostate cancer is the second most common cancer in American men. The development of alternative preventative and/or treatment options utilizing a combination of phytochemicals and chemotherapeutic drugs could be an attractive alternative compared to conventional carcinoma treatments. Genistein isoflavone is the primary dietary phytochemical found in soy and has demonstrated anti-tumor activities in LNCaP prostate cancer cells. Topotecan Hydrochloride (Hycamtin) is an FDA-approved chemotherapy for secondary treatment of lung, ovarian and cervical cancers. The purpose of this study was to detail the potential activation of the intrinsic apoptotic pathway in LNCaP prostate cancer cells through genistein-topotecan combination treatments. Methods: LNCaP cells were cultured in complete RPMI medium in a monolayer (70-80% confluency) at 37ºC and 5% CO2. Treatment consisted of single and combination groups of genistein and topotecan for 24 hours. The treated cells were assayed for i) growth inhibition through trypan blue exclusion assay and microphotography, ii) classification of cellular death through acridine/ ethidium bromide fluorescent staining, and iii) activation of the intrinsic apoptotic pathway through Jc-1: mitochondrial membrane potential assay, cytochrome c release and Bcl-2 protein expression.Results: The overall data indicated that genistein-topotecan combination was significantly more efficacious in reducing the prostate carcinoma’s viability compared to the single treatment options. In all treatment groups, cell death occurred primarily through the activation of the intrinsic apoptotic pathway.Conclusion: The combination of topotecan and genistein has the potential to lead to treatment options with equal therapeutic efficiency as traditional chemo- and radiation therapies, but lower cell cytotoxicity and fewer side effects in patients. Key words: topotecan; genistein; intrinsic apoptotic cell death

Sign in / Sign up

Export Citation Format

Share Document